Pregnancy RSV vaccine slashes newborn hospital admissions by over 80%

A vaccine given during pregnancy is significantly cutting hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials reporting a decrease of more than 80 per cent. The jab, offered to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by enhancing maternal immunity and passing protection through the placenta. A major new study examining nearly 300,000 births across England between September 2024 and March 2025 has shown the vaccine’s “excellent protection” during the period when infants are particularly susceptible to the virus. RSV affects roughly half of all newborns and remains one of the primary reasons of hospital admission in babies under one year old, with more than 20,000 serious cases documented annually across the UK.

How the immunisation protects at-risk babies

RSV, or respiratory syncytial virus, is a common respiratory infection that affects roughly half of all newborns in their first few months of life. The virus can vary from causing mild, cold-like symptoms to causing severe chest infections that cause babies to struggle to breathe and feed. In the most severe cases, the inflammation in the lungs becomes life-threatening, with small numbers of babies dying from the infection each year. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the distressing nature of serious RSV infections: “In babies with severe infections you can see their chest and lungs working hard, as they attempt to draw enough oxygen in. This is very, very frightening as a parent, frightening with good reason.”

The pregnancy vaccine works by stimulating the mother’s body’s defences to generate protective antibodies, which are then transferred to the developing baby through the placenta. This maternal immunity offers newborns with immediate protection from the point of delivery, exactly when they are most vulnerable to RSV. The new study demonstrates that protection reaches nearly 85 per cent when the vaccine is given four weeks or more before delivery. Even briefer gaps between vaccination and birth can still deliver substantial defence, with evidence suggesting that a fortnight’s interval is adequate to shield babies delivered prematurely. Dr Watson recommends pregnant women to receive the vaccine on schedule, whilst observing that protection can still occur even if administered later in the third trimester.

• Nearly 85% coverage when immunised 4 weeks before birth
• Maternal antibodies transferred through the placenta safeguard newborns from day one
• Protection achievable with 2-week gap before premature birth
• Vaccination in the third trimester still offers meaningful protection for infants

Compelling evidence from the latest research

The effectiveness of the RSV vaccine administered during pregnancy has been demonstrated through a thorough investigation undertaken in England, reviewing data from nearly 300,000 babies born between September 2024 and March 2025. This accounts for approximately 90% of all births during that half-year window, providing strong and reliable information of the vaccine’s real-world impact. The study’s results have been endorsed by the UK Health Security Agency as showing strong protection for newborns during their earliest and most vulnerable period. The breadth of this investigation gives healthcare professionals and parents-to-be with trust in the vaccine’s established performance across diverse populations and circumstances.

The results present a striking picture of the vaccine’s ability to protect. More than 4,500 babies were treated in hospital with RSV during the study period, with the vast majority being infants whose mothers had not received the vaccination. This clear distinction highlights the vaccine’s critical role in reducing the risk of serious illness in newborns. The drop in hospital admissions surpassing 80 per cent represents a major public health success, potentially preventing thousands of infants from experiencing the alarming and potentially severe symptoms associated with severe RSV infection. These findings strengthen the importance of the vaccination programme established in the UK in 2024.

Methodology and scope of study

The research examined birth and hospitalisation records from England over a six-month period, capturing data on approximately 90 per cent of all births during this timeframe. By examining around 300,000 babies born to both vaccinated and unvaccinated mothers, researchers were in a position to determine direct comparisons of RSV infection rates and hospitalisations. The large sample size and comprehensive nature of the data collection ensured that findings were statistically robust and indicative of the general population, rather than isolated cases or limited subgroups.

The study specifically monitored hospital admissions for RSV among infants born to mothers who had received the vaccine at differing periods before delivery. This allowed researchers to establish the least amount of time between vaccination and birth for best possible protection, as well as to determine whether protection stayed significant with reduced timeperiods. The methodology measured actual clinical results rather than laboratory-based settings, providing tangible evidence of how the vaccine works when given across varied healthcare environments and patient circumstances throughout the third trimester of pregnancy.

Grasping RSV and its hazards

Respiratory syncytial virus, commonly referred to as RSV, is among the primary causes of hospital admission in infants aged under twelve months across the United Kingdom. The virus affects approximately half of all newborns during their early months of life, with severity changing substantially from mild cold-like symptoms to serious, potentially fatal chest infections. Over 20,000 infants require serious hospital treatment for RSV annually in the UK alone, placing enormous strain on children’s wards and newborn care units during peak seasons.

The infection causes deep inflammation in the lungs and airways, making it extremely challenging for vulnerable newborns to breathe and feed properly. Parents often witness their babies struggling visibly, their chests heaving as they work to get adequate oxygen into their damaged lungs. Whilst the majority of babies improve through palliative treatment, a modest yet notable number die from RSV-related complications yearly, making immunisation programmes a vital health service priority for protecting the most vulnerable and youngest members of society.

• RSV produces inflammation in lungs, leading to severe breathing difficulties in infants
• Nearly 50% of newborns contract the virus in their first few months of life
• Symptoms range from mild colds to serious chest infections that threaten life requiring hospitalisation
• More than 20,000 UK babies require serious hospital care for RSV annually
• A small number of infants die from RSV complications annually in the UK

Uptake rates and specialist advice

Since the RSV vaccine programme launched in 2024, health officials have highlighted the value of pregnant women getting their jab at the optimal time for greatest protection. Dr Conall Watson, lead for the national programme for RSV at the UK Health Security Agency, has emphasised that timing is crucial for ensuring newborns receive the maximum immunity from birth. Whilst the study demonstrates that vaccination at least four weeks before delivery provides approximately 85% protection, experts advise women to receive their vaccine as early as possible from 28 weeks of pregnancy forward to maximise the antibodies transferred to their babies via the placenta.

The messaging from health authorities remains clear: pregnant women should make a priority of vaccination during their third trimester, even if circumstances mean they cannot get vaccinated at the optimal time. Dr Watson has reassured expectant mothers that protection is still achievable with reduced timeframes between immunisation and delivery, including even a fourteen-day window for those giving birth ahead of schedule. This flexible approach acknowledges the realities of pregnancy and childbirth whilst maintaining strong protection for vulnerable newborns during their most critical early months when RSV represents the highest danger of serious illness.

Regional disparities in immunisation

Whilst the RSV vaccine programme has been rolled out across England, uptake rates and deployment schedules have varied across various areas and NHS trusts. Some areas have attained greater immunisation rates among qualifying expectant mothers, whilst others continue working to increase awareness and availability of the jab. These geographical variations demonstrate variations in medical facilities, engagement approaches, and community involvement initiatives, though the overall statistics demonstrates consistently strong protection irrespective of geographical location.

• NHS trusts rolling out varied communication campaigns to connect with women during pregnancy
• Geographic variations in immunisation take-up throughout England demand focused enhancement
• Regional health providers tailoring initiatives to align with local requirements and situations

Real-world impact and parental perspectives

The vaccine’s impressive effectiveness translates into concrete gains for families throughout the United Kingdom. With over 20,000 babies admitted to hospital annually due to RSV prior to the introduction of this safeguarding intervention, the 80% drop in admissions equates to thousands of infants shielded from serious illness. Parents no more face the troubling prospect of watching their newborns struggle for breath or difficulty feeding, symptoms that mark severe RSV infections. The vaccine has fundamentally shifted the terrain of neonatal respiratory health, offering expectant mothers a preventative option to shield their most at-risk babies during those vital initial period.

For families like that of Malachi, whose serious RSV infection resulted in severe brain damage, the vaccine’s introduction carries deep personal significance. His mother’s support of the jab underscores the life-altering consequences that preventable illness can have on young children and their families. Whilst Malachi’s experience predates the vaccine programme, his story resonates strongly with parents now offered protection. The knowledge that such significant complications—hospital admission, oxygen dependency, neurological damage—are now largely avoidable has given considerable reassurance to expectant mothers in their final trimester, converting what was once an unavoidable seasonal threat into a controllable health concern.